← Back to Search

Stem Cell Transplantation

Busulfan for Pediatric Disorders (UCB Trial)

N/A

Waitlist Available

Led By Caridad Martinez, MD

Research Sponsored by Baylor College of Medicine

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be younger than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 3 years

Awards & highlights

UCB Trial Summary

This trial will enroll up to 60 participants.

UCB Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 3 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~3 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Overall Survival at 1 Year After Umbilical Cord Blood Transplant in Pediatric Patients.

Overall Survival at 100 Days After Umbilical Cord Blood Transplant in Pediatric Patients.

Overall Survival at 3 Years After Umbilical Cord Blood Transplant in Pediatric Patients.

Secondary outcome measures

Incidence of Severe Grade III-IV Acute GvHD at Day 100.

Number of Participants With Chronic GvHD

Number of Participants With Donor Engraftment After Transplant.

+2 more

UCB Trial Design

1Treatment groups

Experimental Treatment

Group I: Umbilical Cord Blood Transplant Treatment PlanExperimental Treatment4 Interventions

Busulfan, Cytoxan, Fludarabine, Cord Blood Stem Cell Infusion

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Busulfan

2008

Completed Phase 3

~1120

Cytoxan

2007

Completed Phase 3

~1460

Fludarabine

2012

Completed Phase 3

~1100

Cord Blood Stem Cell Infusion

2010

N/A

~60

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Baylor College of MedicineLead Sponsor

1,001 Previous Clinical Trials

6,002,140 Total Patients Enrolled

Center for Cell and Gene Therapy, Baylor College of MedicineOTHER

111 Previous Clinical Trials

2,777 Total Patients Enrolled

Caridad Martinez, MDPrincipal InvestigatorBaylor College of Medicine

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any opportunities to enroll in this research experiment at present?

"At this time, no more patients are being recruited for this trial. The original post was on September 1st 2009 and the latest update was February 4th 2022. However, there are 925 studies searching for new participants with disease and 914 trials actively enrolling in Busulfan currently available."

Answered by AI

How is Busulfan typically employed therapeutically?

"Busulfan has been traditionally used to treat multiple sclerosis and can be beneficial in managing various other medical conditions, including allogeneic hematopoietic stem cell transplant, chronic myelogenous leukemia, thrombocythemia essential and acute or chronic leukemias."

Answered by AI

How many participants are currently participating in this research study?

"This research project is no longer seeking patients for participation. Initially posted on September 1st 2009, the trial was last updated on February 4th 2022. For those looking to join different clinical trials, there are currently 925 ongoing studies with various conditions and a further 914 recruiting volunteers for Busulfan treatment."

Answered by AI

Is there any existing precedent for using Busulfan in research?

"As of now, Busulfan is the subject of 914 clinical trials, 162 of which are in Phase 3. The vast majority are based out of Philadelphia, Pennsylvania with 28674 total sites running these studies."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Umbilical Cord Blood Transplant for Congenital Pediatric Disorders

Caridad Martinez 2009. "Umbilical Cord Blood Transplant for Congenital Pediatric Disorders". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00950846.